2 hot FTSE 100 dividend stocks I’d buy in February

These two shares offer excellent income potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Buying dividend stocks has generally been a sound strategy in recent years. Low levels of inflation plus low interest rates have resulted in higher-yielding shares becoming more popular. Even though inflation is expected to rise, companies that offer growing dividends and a relatively high yield should still prove popular in 2017. Here are two stocks which offer just that combination, as well as wide margins of safety through low valuations.

A growing life insurer

Aviva‘s (LSE: AV) decision to merge with Friends Life has thus far proven to be highly successful. The expected synergies are on target to be delivered and the combined entity should provide greater resilience in future years. It should be a more dominant player within the life insurance space and, since Brexit is unlikely to have a major impact on the business, its risk profile remains relatively low.

The company’s yield of 5.4% is around 180 basis points higher than the FTSE 100’s yield. Furthermore, it is likely to rise at a faster pace than that of the wider index, since Aviva is likely to raise dividends by at least as much as earnings growth over the medium term. Since it is forecast to post a rise in earnings of 14% this year, followed by 6% next year, this should easily beat inflation. The company could even be yielding over 6% within a couple of years.

Should you invest £1,000 in Aviva right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Aviva made the list?

See the 6 stocks

Aviva trades on a price-to-earnings (P/E) ratio of 9.6. While there is scope for the FTSE 100’s value to come under pressure since it is near to a record high, the company’s valuation indicates it offers an attractive risk/reward ratio.

A recovering healthcare play

AstraZeneca (LSE: AZN) may seem like an unlikely choice as an income stock. Certainty, at 5.2% it yields well in excess of the FTSE 100. However, it has not raised dividends in recent years, as its loss of patents has led to significant declines in earnings.

This situation is forecast to change. Although the company’s bottom line is expected to fall by 9% this year, growth is anticipated from 2018. In the 2018 financial year, AstraZeneca’s net profit is due to rise by 11% and this could be the start of a period of better performance for the business. It has a strong pipeline of potential treatments thanks to major investment in recent years. And with a growing bottom line could come a rising dividend. In fact, in 2018 its shareholder payouts are expected to rise by 2.2%.

Since AstraZeneca trades on a P/E ratio of 12.6, it appears to offer excellent value for money. Upward re-rating potential is high, especially since historically it has had a P/E ratio which is in the mid to late teens. Therefore, its shares could offer defensive appeal in 2017 during what could be a challenging period for the wider market. When combined with its bright income potential, this makes the stock a standout dividend play.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and Aviva. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

What the devil’s going on with the HSBC share price?

The HSBC share price has actually been less volatile than some of its peers, despite its Chinese operations suggesting it’s…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Are Tesco shares a screaming buy after sinking to 9-month lows?

Tesco shares continue to experience price weakness as signs of mounting competition grow. But is it now too cheap to…

Read more »

Investing Articles

Down 31%! 1 top growth stock to consider at $10 for a Stocks and Shares ISA

This high-quality stock has pulled back sharply since November, making it a possible candidate for a growth-oriented Stocks and Shares…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now?

AstraZeneca’s share price has fallen a long way from its September high, but this may mean an opportunity for me…

Read more »

Investing Articles

Is April a great time to start investing?

Our writer spotlights a top-tier tech stock that has sold off recently, making it worthy of consideration for someone ready…

Read more »

Investing Articles

1 beaten down dividend stock investors could consider for passive income

Our writer Ken Hall takes a look at one under-pressure mining giant that should be on investors' radars as a…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

3 FTSE 100 investment trusts to consider for a new ISA in 2025

It's a new tax year and time to dust off that old ISA. Here are three FTSE 100 investment trusts…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Is there still time to pick up Nvidia stock cheaply?

The Nvidia stock price has just had a scary week. But here's why I expect that should have very little…

Read more »